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Cisplatin is an effective antitumour agent against a variety of
neoplasms (Gottlieb & Drewinko, 1975; Yagoda et al., 1976;
Einhorn, 1979; Young et al., 1979) but its nephrotoxic
properties limit the therapeutic dose (Madias & Harrington,
1978; Krakoff, 1979). Attempts at overcoming nephrotoxicity
have involved regimens incorporating hydration, chloruresis
(Earhart et al., 1983), diethyldithiocarbamate rescue (Dedon
et al., 1985), sodium thiosulphate (Howell et al., 1983) and
drug administration in hypertonic saline (Litterst, 1981;
Ozols et al., 1984). There is some controversy as to whether
some of these procedures reduce the therapeutic index by
giving additional protection to the tumour. Cisplatin is
hydrolysed at the chloride positions to produce the cytotoxic
species (Rosenberg, 1979) and therefore it would be expected
that when cisplatin is in a high chloride milieu, its toxicity
would be reduced. Aamdal et al. (1984) showed that there
was a reduced antitumour effect of cisplatin in mice which
received the drug in a high sodium chloride vehicle.
It could be argued that reducing the chloride
concentration in the drug vehicle might enhance cisplatin
toxicity, thus enabling a lower dose to be given. This in vitro
study examines the effect of reducing the chloride
concentration, with concomitant reductions in osmolarity, on
the cytotoxicity of cis-diamminedichloroplatinum (II) (cis-
platin), cis-dichloro-trans-dihydroxy-cis-bis (isopropylamine)
platinum (IV) (CHIP) and diammine (1,1-cyclobutane-
dicarboxylato) platinum (II) (carboplatin). The results were
compared with two other anticancer agents, adriamycin and
melphalan. A preliminary report of this work was presented
at a recent symposium of Platinum Cancer Chemotherapy
(Smith et al., 1987). Groos et al. (1986) have also shown that
the cisplatin sensitivity of the cell line RTI12, derived from a
transitional cell carcinoma of the human bladder, was
increased if the osmotic strength of the cell culture medium
was reduced. They concluded that the therapeutic value of
intravesical chemotherapy for superficial bladder cancer
might be enhanced if the osmotic strength of the instillate
was reduced.
The chloride concentration in the cell culture medium was
reduced by simple dilution with distilled water. The medium
was diluted by up to 20% (i.e. 2ml of distilled water to 8ml
of medium). This would cause slight cell swelling but did not
alter the cell viability during the period of drug exposure.
Chinese hamster ovary (CHO) cells grown in suspension
were treated with a fixed drug dose for one hour at 37°C in
culture medium diluted to different osmolarities. Cells were
then plated and their clonogenicity was assessed by staining
and counting the number of colonies after 7 days at 37°C.
The content of platinum in treated cells was determined by
atomic absorption spectrophotometry on an IL 157 single
beam instrument retrofitted with an IL655 furnace atomiser
using an in tube digestion method. Treated cell suspensions
were washed twice with saline at 4°C and the cell pellets
resuspended in 0.5% nitric acid. Cell extracts (25pl) were
then estimated for Pt content. A standard curve was
determined by spiking untreated cell extracts with
appropriate concentrations of the platinum drug.
Correspondence: E. Smith.
Figure 1 shows that all three platinum agents are more
cytotoxic as the osmolarity/chloride concentration is reduced.
While this may not seem surprising for cisplatin and CHIP,
as they both contain chloride groups, carboplatin has no
chloride groups in its configuration. Thus it would appear
that changes in osmolarity are more important than the
chloride concentration per se. This was confirmed by the fact
that if the chloride concentration was reduced, but the
osmolarity maintained, then there was no effect on platinum
toxicity.
The slight cell swelling which occurs in hypotonic medium
may be causing an increase in drug uptake. For all three
agents we found a significant increase in cellular platinum
content by reducing the osmolarity. Figure 2 shows the data
obtained with cisplatin. Reducing the osmolarity from
300mosmI1- (normal) to 240mosmI1- caused a three-fold
increase in platinum uptake. Similar reductions in osmolarity
caused a two-fold increase in platinum uptake with CHIP
and a six-fold increase in platinum uptake with carboplatin
(Figure 3). Andrews et al. (1988) also found increased uptake
of cisplatin by reducing the osmolarity but he did not do a
comparative cell survival study or look at any other
platinum drugs.
For comparison we also looked at the effect of reduced
osmolarity on melphalan and adriamycin cytotoxicity. Figure
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Figure 1 The effect of varying osmolarity on the cytotoxicity of
25/M cisplatin (0), 5OM CHIP (0) and 500,M carboplatin
(x). Drug treatments were for one hour at 37°C on CHO cells.
Undiluted culture medium is approximately 30mosml-1.
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Figure 2 The uptake of platinum by CHO cells after a 1 h
exposure to 25gM cisplatin at 37°C under varying conditions of
osmolarity.
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Figure 3 The uptake of platinum by CHO cells after a 1 h
exposure to 500pM CHIP (x) or 500pM carboplatin (0) at
370C under varying conditions of osmolarity.
4 shows that the toxicities of these agents were not
significantly modified. Thus, our observations with the
platinum compounds are by no means a general
phenomenon attributable to slight cell swelling.
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Figure 4 The effect of varying osmolarity on the cytotoxicity of
1gM adriamycin ( x ) and 1jigml -1 melphalan (@). Drug
treatments were for 1 h at 37°C on CHO cells.
Hypotonic solutions are known to result in a de-
condensation of chromatin (Brasch et al., 1972). Oleinick et
al. (1987) have shown that DNA protein cross-link (DPC)
formation is enhanced by hypotonic medium which is
consistent with the opening of condensed chromatin. DPC
are formed by a variety of radiations and chemicals
including cisplatin. The enhanced toxicity of the three
platinum drugs in hypotonic medium may, therefore, be due
to an increase in platinum binding to DNA at active sites,
resulting in cytotoxic lesions.
In conclusion, these data would suggest that conditions of
osmolarity may be more relevant to platinum toxicity than
chloride concentration per se. Only minimal changes in
osmolarity can be achieved in vivo due to the efficient
osmoregulatory systems in operation, but even small changes
might be exploited in order to improve platinum drug
therapy. The tumour microenvironment within solid tumours
may be hypertonic, as a result of the build-up of catabolites,
which cannot be removed by the poor vascular supply of the
tumour. This may be a potential explanation for poor
tumour responses in many solid tumours treated with
platinum chemotherapy.
This work was supported by a grant from the Cancer Research
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